| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1968) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent Prodrug |
| ATC: | L04AX01 |
| UNII: | MRK240IY2L |
Structure
| InChI Key | LMEKQMALGUDUQG-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C9H7N7O2S |
| Molecular Weight | 277.27 |
| AlogP | 1.15 |
| Hydrogen Bond Acceptor | 8.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 115.42 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 19.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Amidophosphoribosyltransferase inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 107 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | - | - | - | 4 |
Metabolites
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Crohn Disease | 3 | D003424 | ClinicalTrials |
| Lupus Erythematosus, Systemic | 3 | D008180 | ClinicalTrials |
| Colitis, Ulcerative | 3 | D003093 | ClinicalTrials |
| Carcinoma, Hepatocellular | 3 | D006528 | ClinicalTrials |
| Cardiomyopathies | 3 | D009202 | ClinicalTrials |
| Myasthenia Gravis | 3 | D009157 | ClinicalTrials |
| Vasculitis | 3 | D014657 | ClinicalTrials |
| Renal Insufficiency, Chronic | 3 | D051436 | ClinicalTrials |
| Glomerulonephritis, IGA | 3 | D005922 | ClinicalTrials |
| Neuromyelitis Optica | 3 | D009471 | ClinicalTrials |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 | D056648 | ClinicalTrials |
| Granulomatosis with Polyangiitis | 3 | D014890 | ClinicalTrials |
| Lupus Nephritis | 3 | D008181 | ClinicalTrials |
| Churg-Strauss Syndrome | 3 | D015267 | ClinicalTrials |
| Microscopic Polyangiitis | 3 | D055953 | ClinicalTrials |
| Takayasu Arteritis | 3 | D013625 | ClinicalTrials |
| Eczema | 3 | D004485 | ClinicalTrials |
| Thrombocytopenia | 3 | D013921 | ClinicalTrials |
| Pulmonary Fibrosis | 3 | D011658 | ClinicalTrials |
| Hepatitis, Autoimmune | 2 | D019693 | ClinicalTrials |
| Gout | 2 | D006073 | ClinicalTrials |
| Pemphigus | 2 | D010392 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 2 | D015470 | ClinicalTrials |
| Anemia, Sickle Cell | 2 | D000755 | ClinicalTrials |
| Pemphigoid, Bullous | 2 | D010391 | ClinicalTrials |
| Idiopathic Pulmonary Fibrosis | 2 | D054990 | ClinicalTrials |
| Lung Diseases | 2 | D008171 | ClinicalTrials |
| Infertility | 2 | D007246 | ClinicalTrials |
| Pemphigus | 2 | D010392 | ClinicalTrials |
| Lung Diseases, Interstitial | 2 | D017563 | ClinicalTrials |
| Mucopolysaccharidoses | 1 | D009083 | ClinicalTrials |
| Myelodysplastic Syndromes | 1 | D009190 | ClinicalTrials |
| Urticaria | 1 | D014581 | ClinicalTrials |
| Inflammatory Bowel Diseases | 1 | D015212 | ClinicalTrials |
Related Entries
Scaffolds
Side Effects from Label
Side Effects (PT)
| Side effects | Relative Frequency (%) | Labels | |
|---|---|---|---|
| Blood and lymphatic system disorders Leukopenia | 28.0 | ||
| Infections and infestations Infection | 20.0 | ||
| Infections and infestations Infection | 1.0 | ||
| Blood and lymphatic system disorders Lymphoma | 0.5 | ||
| Blood and lymphatic system disorders Non-Hodgkin's lymphoma | 0.5 |
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 446-86-6 |
| ChEBI | 2948 |
| ChEMBL | CHEMBL1542 |
| DrugBank | DB00993 |
| DrugCentral | 269 |
| EPA CompTox | DTXSID4020119 |
| FDA SRS | MRK240IY2L |
| Human Metabolome Database | HMDB0015128 |
| Guide to Pharmacology | 7120 |
| KEGG | C06837 |
| PharmGKB | PA448515 |
| PubChem | 2265 |
| SureChEMBL | SCHEMBL4278 |
| ZINC | ZINC000004258316 |
CONTENTS